756
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Current situation of the Pharmacogenetics of Immune Recovery in Treated HIV-Infected Patients

, , &
Pages 569-572 | Published online: 05 May 2014

References

  • Gaardbo JC , HartlingHJ, GerstoftJ, NielsenSD. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin. Dev. Immunol.670957 , 1–17 (2012).
  • Battegay M , NüeschR, HirschelB et al. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect. Dis. 6(5) , 280–287 (2006).
  • Mallal S , PhillipsE, CarosiG et al. HLAB*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358 , 568–579 (2008).
  • Vidal F , López-DuplaM, LagunoM et al. Pharmacogenetics of efficacy and safety of HCV treatment in HCV–HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants. PLoS ONE 7 , e47725 (2012).
  • Asboe D , AitkenC, BoffitoM et al. British HIV association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med. 13 , 1–44 (2012).
  • European Association for the study of the liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. (2013) (Epub December 4) (In Press).
  • Peraire J , ViladésC, PachecoYM et al. Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients. Expert Opin. Drug Metab. Toxicol. 10 , 81–101 (2014).
  • Nakajima T , KimuraA. Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of a benefit of an earlier initiation of HAART. Pharmacogenomics9 , 1347–1351 (2008).
  • Haas DW , KuritzkesDR, RitchieMD et al. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin. Trials 12 , 277–285 (2011).
  • Ahuja SK , KulkarniH, CatanoG et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14 , 413–420 (2008).
  • Hendrickson SL , JacobsonLP, NelsonGW et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS free survival. J. Acquir. Immune Defic. Syndr. 48 , 263–271 (2008).
  • Haas DW , GeraghtyDE, AndersenJ et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trials Group Study. J. Infect. Dis. 194 , 1098–1107 (2006).
  • Rasajuriar R , BoothD, SolomonA et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J. Infect. Dis. 202 , 1254–1264 (2010).
  • Rasajuriar R , BoothDR, GoillouM et al. The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive HAART. Genes Immun. 13 , 83–93 (2012).
  • Nasi M , PintiM, BugariniR et al. Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence in the rise in CD4+ T cell count after antiretroviral therapy in drug-naive HIV-positive patients. Immunogenetics 57 , 628–635 (2005).
  • Grady BJ , SamuelsDC, RobbinsGK et al. Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS Clinical Trials Group Study 384. J. Acquir. Immune Defic. Syndr. 58 , 363–370 (2011).
  • Guzmán-Fulgencio M , BerenguerJ, MicheloudD et al. European mitochondrial haplogroups are associated with CD4+ T-cell recovery in HIV-infected patients on combination antiretroviral therapy. J. Antimicrob. Chemother. 68 , 2349–2357 (2013).
  • Brumme ZL , BrummeCJ, ChuiC et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J. Infect. Dis. 195 , 1694–1704 (2007).
  • Fellay J , MarzoliniC, MeadenER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetic study. Lancet 352 , 30–36 (2002).
  • Habtewold A , AmogneW, MakonnenE et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J. Antimicrob. Chemother. 66 , 2350–2361 (2011).
  • van Manen D , van‘t Wout AB, Schuitemaker H. Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenetics. Retrovirology9 , 70 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.